Prostate cancer remains dependent of androgen receptor (AR) signalling, even after emergence of castration resistance. EZN-4176 is a third-generation antisense oligonucleotide that binds to the hinge ...

Patients with advanced malignancies were enrolled in dose-escalating cohorts (3 + 3 design). EZN-2208 was administered as a 1-h intravenous infusion given weekly for 3 weeks per each 4-week cycle.

EZN-2968 is a potent locked nucleic acid antisense oligonucleotide suppressing HIF-1α mRNA translation in vitro (IC50 ∼1–5 nM). Methods: This study was designed to determine the safety, tolerability, ...

This study looked at a drug called EZN 4176 for prostate cancer that has spread to another part of the body and is no longer responding to hormone therapy. Doctors often use hormone therapy to treat ...

Predictive and prognostic markers of recurrence after resection of primary or metastatic colorectal cancer. Background: EZN-2208 is a water-soluble, parenterally-delivered PEGylated conjugate of SN38 ...